The role of inhibiting GM-CSF/GM-CSF–receptor interaction in treating patients with COVID-19 is currently under investigation in several clinical studies (ClinicalTrials.Gov, 2020a; ClinicalTrials.Gov, 2020b; ClinicalTrials.Gov, 2020e; ClinicalTrials.Gov, 2020g; ClinicalTrials.Gov, 2020h; De Luca et al., 2020; Temesgen et al., 2020). Here, CSF2 is linked to COVID-19.